勃林格殷格翰和微软正在合作研究在临床试验中使用数字患者孪生。目标是确定疾病进展预测模型是否可以改进试验设计并可能减少对大型对照组的需求，首先从肺部健康研究开始。 AI
影响 此次合作可能带来更高效的临床试验，缩短新药上市的时间和成本。
排序理由 制药公司与科技巨头之间的合作伙伴关系，以探索AI的特定应用。
在 Mastodon — mastodon.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →
勃林格殷格翰和微软探索用于临床试验的数字患者孪生
本文如何被排名
- Signal score
- 10 / 100
- Composite score across the factors below. Higher = stronger signal that this story matters right now.
- Newsworthiness bucket
- Tool
- 制药公司与科技巨头之间的合作伙伴关系，以探索AI的特定应用。
- Source corroboration
- Single-source cluster
- Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
- Topics
- product, other
- Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
- AI-industry relevance
- High
- Clearly on-topic for AI-industry coverage.
- Story freshness
- Breaking (< 6h)
- Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.
完整方法见我们的编辑标准。
报道来源 [1]
-
数字患者孪生能否帮助临床试验以更少的参与者获得可靠的答案？勃林格殷格翰和微软将探索模型是否
Could digital patient twins help clinical trials reach reliable answers with fewer participants? Boehringer Ingelheim and Microsoft will explore whether models forecasting disease progression can improve trial design and reduce control-group sizes, starting with lung health. http…